Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

SAN DIEGO — Ar­cel­lx raised the cur­tain on the CAR-T da­ta it will present on Mon­day at the Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence as it read­ies a mul­ti­year plan to take on J&J and Leg­end Biotech’s Carvyk­ti, as well as Bris­tol My­ers Squibb’s Abec­ma.

Da­ta from a Phase I mul­ti­ple myelo­ma study for Ar­cel­lx’s an­i­to-cel, for­mer­ly known as CART-ddBC­MA, showed a 100% over­all re­sponse rate in 38 evalu­able pa­tients, in­clud­ing 29 (76%) with a com­plete re­sponse. Ad­di­tion­al­ly, in a group of 28 pa­tients evalu­able for min­i­mal resid­ual dis­ease (MRD) test­ing, me­di­an du­ra­tion of re­sponse, pro­gres­sion-free sur­vival and over­all sur­vival mea­sures have not yet been reached.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER